| Synonym |
| Thai / English name |
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Case reportN(Total) : 1N(Treatment) : 1Sex : MaleAge : 26 yrs.Route : Oral administrationDose/Conc.(herb) : Daily ingestion of Panax ginseng via energy drinksDuration : 3 monthsType of interaction : PharmacodynamicsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 400 mg dailyResult : PositiveRemark :Note : A 26-year-old man with chronic myelogenous leukemia who had taken imatinib 400 mg daily for 7 years with no complications presented with right upper quadrant pain. Laboratory test results included alanine aminotransferase 1069 U/L, aspartate aminotransferase 481 U/L, alkaline phosphatase 124 IU/L, total bilirubin 1.4 mg/dL, albumin 4.0 g/dL, and international normalized ratio 1.08. Liver biopsy showed acute lobular hepatitis favoring a drug-induced etiology, and a diagnosis of imatinib-induced hepatotoxicity was made. The patient's only lifestyle modification prior to the diagnosis of hepatotoxicity was daily ingestion of Panax ginseng via energy drinks for the past 3 months. Both imatinib and ginseng were discontinued, and the patient was treated with a short course of corticosteroids. Imatinib was later restarted at the same dose with no recurrent elevations in his liver enzyme levels. They propose that the patien's late-onset imatinib-associated hepatotoxicity was due to an interaction between ginseng and imatinib through CYP3A4.
Part Used : รากActivity : HEPATOTOXIC ACTIVITYSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Case reportN(Total) : 1N(Treatment) : 1Sex : MaleAge : 26 yrs.Route : Oral administrationDose/Conc.(herb) : Daily ingestion of Panax ginseng via energy drinksDuration : 3 monthsType of interaction : PharmacodynamicsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 400 mg dailyResult : PositiveRemark :Note : A 26-year-old man with chronic myelogenous leukemia who had taken imatinib 400 mg daily for 7 years with no complications presented with right upper quadrant pain. Laboratory test results included alanine aminotransferase 1069 U/L, aspartate aminotransferase 481 U/L, alkaline phosphatase 124 IU/L, total bilirubin 1.4 mg/dL, albumin 4.0 g/dL, and international normalized ratio 1.08. Liver biopsy showed acute lobular hepatitis favoring a drug-induced etiology, and a diagnosis of imatinib-induced hepatotoxicity was made. The patient's only lifestyle modification prior to the diagnosis of hepatotoxicity was daily ingestion of Panax ginseng via energy drinks for the past 3 months. Both imatinib and ginseng were discontinued, and the patient was treated with a short course of corticosteroids. Imatinib was later restarted at the same dose with no recurrent elevations in his liver enzyme levels. They propose that the patien's late-onset imatinib-associated hepatotoxicity was due to an interaction between ginseng and imatinib through CYP3A4.
Part Used : รากActivity : CYTOCHROME P-450 INHIBITIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Case reportN(Total) : -N(Treatment) : -Sex : MaleAge : 26 yrs.Route : Oral administrationDose/Conc.(herb) : Daily ingestion of panax ginseng via energy drinksDuration : 3 monthsType of interaction : PharmacokineticsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 400 mg dailyResult : PositiveRemark : The patient's daily ingestion of ginseng led to reduced CYP3A4 activity, which subsequently decreased the metabolism of imatinib. Compromised imatinib metabolism increased its plasma concentration, thus potentiating its hepatotoxic effect.Note : A 26-year-old man with chronic myelogenous leukemia who had taken imatinib 400 mg daily for 7 years with no complications presented with right upper quadrant pain. Laboratory test results included alanine aminotransferase 1069 U/L, aspartate aminotransferase 481 U/L, alkaline phosphatase 124 IU/L, total bilirubin 1.4 mg/dL, albumin 4.0 g/dL, and international normalized ratio 1.08. Liver biopsy showed acute lobular hepatitis favoring a drug-induced etiology, and a diagnosis of imatinib-induced hepatotoxicity was made. The patient's only lifestyle modification prior to the diagnosis of hepatotoxicity was daily ingestion of Panax ginseng via energy drinks for the past 3 months. Both imatinib and ginseng were discontinued, and the patient was treated with a short course of corticosteroids. Imatinib was later restarted at the same dose with no recurrent elevations in his liver enzyme levels. They propose that the patien's late-onset imatinib-associated hepatotoxicity was due to an interaction between ginseng and imatinib through CYP3A4.
Part Used : รากActivity : CYTOTOXIC ACTIVITYSolvent/Active Compound : waterType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 microgram/mlDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 0.1 micromolarResult : PositiveRemark : Treated KBM-5, K562, THP-1, U266, and MM1.S cells with KRGE in combination with IM for 24 h, and then examined the cell viability with an MTT assay. The results found that KRGE indeed enhanced the cytotoxic effects of IM only in KBM-5 cells. The combination treatment indeed enhanced apoptosis by activation of caspase-3 and induced PARP cleavage, suppressed antiapoptosis and proliferative proteins expression, decreased the phosphorylation of p38, STAT5, and p53 in KBM-5 cells and inhibited STAT5-DNA binding activities. These results show that KRGE and IM can abrogate the DNA binding ability of STAT5.Note : Imatinib mesylate = IM
Part Used : รากActivity : POLY(ADP-RIBOSE) POLYMERASE INHIBITIONSolvent/Active Compound : waterType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 microgram/mlDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 0.1 micromolarResult : PositiveRemark : Treated KBM-5, K562, THP-1, U266, and MM1.S cells with KRGE in combination with IM for 24 h, and then examined the cell viability with an MTT assay. The results found that KRGE indeed enhanced the cytotoxic effects of IM only in KBM-5 cells. The combination treatment indeed enhanced apoptosis by activation of caspase-3 and induced PARP cleavage, suppressed antiapoptosis and proliferative proteins expression, decreased the phosphorylation of p38, STAT5, and p53 in KBM-5 cells and inhibited STAT5-DNA binding activities. These results show that KRGE and IM can abrogate the DNA binding ability of STAT5.Note : Imatinib mesylate = IM
Part Used : รากActivity : CASPASE-3 STIMULATIONSolvent/Active Compound : waterType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 microgram/mlDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 0.1 micromolarResult : PositiveRemark : Treated KBM-5, K562, THP-1, U266, and MM1.S cells with KRGE in combination with IM for 24 h, and then examined the cell viability with an MTT assay. The results found that KRGE indeed enhanced the cytotoxic effects of IM only in KBM-5 cells. The combination treatment indeed enhanced apoptosis by activation of caspase-3 and induced PARP cleavage, suppressed antiapoptosis and proliferative proteins expression, decreased the phosphorylation of p38, STAT5, and p53 in KBM-5 cells and inhibited STAT5-DNA binding activities. These results show that KRGE and IM can abrogate the DNA binding ability of STAT5.Note : Imatinib mesylate = IM
Part Used : รากActivity : PROTEIN PHOSPHORYLATION DECREASESolvent/Active Compound : waterType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 microgram/mlDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 0.1 micromolarResult : PositiveRemark : Treated KBM-5, K562, THP-1, U266, and MM1.S cells with KRGE in combination with IM for 24 h, and then examined the cell viability with an MTT assay. The results found that KRGE indeed enhanced the cytotoxic effects of IM only in KBM-5 cells. The combination treatment indeed enhanced apoptosis by activation of caspase-3 and induced PARP cleavage, suppressed antiapoptosis and proliferative proteins expression, decreased the phosphorylation of p38, STAT5, and p53 in KBM-5 cells and inhibited STAT5-DNA binding activities. These results show that KRGE and IM can abrogate the DNA binding ability of STAT5.Note : Imatinib mesylate = IM
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : waterType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 microgram/mlDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 0.1 micromolarResult : PositiveRemark : Treated KBM-5, K562, THP-1, U266, and MM1.S cells with KRGE in combination with IM for 24 h, and then examined the cell viability with an MTT assay. The results found that KRGE indeed enhanced the cytotoxic effects of IM only in KBM-5 cells. The combination treatment indeed enhanced apoptosis by activation of caspase-3 and induced PARP cleavage, suppressed antiapoptosis and proliferative proteins expression, decreased the phosphorylation of p38, STAT5, and p53 in KBM-5 cells and inhibited STAT5-DNA binding activities. These results show that KRGE and IM can abrogate the DNA binding ability of STAT5.Note : Imatinib mesylate = IM
Part Used : รากActivity : APOPTOSIS INDUCTIONSolvent/Active Compound : waterType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 microgram/mlDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 0.1 micromolarResult : PositiveRemark : Treated KBM-5, K562, THP-1, U266, and MM1.S cells with KRGE in combination with IM for 24 h, and then examined the cell viability with an MTT assay. The results found that KRGE indeed enhanced the cytotoxic effects of IM only in KBM-5 cells. The combination treatment indeed enhanced apoptosis by activation of caspase-3 and induced PARP cleavage, suppressed antiapoptosis and proliferative proteins expression, decreased the phosphorylation of p38, STAT5, and p53 in KBM-5 cells and inhibited STAT5-DNA binding activities. These results show that KRGE and IM can abrogate the DNA binding ability of STAT5.Note : Imatinib mesylate = IM
Part Used : รากActivity : PROTEIN EXPRESSION INHIBITIONSolvent/Active Compound : waterType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 microgram/mlDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Imatinib*/Glivec/Imatinib mesylateDose/Conc.(drug) : 0.1 micromolarResult : PositiveRemark : Treated KBM-5, K562, THP-1, U266, and MM1.S cells with KRGE in combination with IM for 24 h, and then examined the cell viability with an MTT assay. The results found that KRGE indeed enhanced the cytotoxic effects of IM only in KBM-5 cells. The combination treatment indeed enhanced apoptosis by activation of caspase-3 and induced PARP cleavage, suppressed antiapoptosis and proliferative proteins expression, decreased the phosphorylation of p38, STAT5, and p53 in KBM-5 cells and inhibited STAT5-DNA binding activities. These results show that KRGE and IM can abrogate the DNA binding ability of STAT5.Note : Imatinib mesylate = IM
